貴州百靈(002424.SZ)與中藥研究所簽訂“防治冠狀病毒性呼吸道感染藥物篩選及藥效評價”研究合作協議
格隆匯2月3日丨貴州百靈(002424.SZ)公佈，公司(“甲方”)於2020年2月1日與中國中醫科學院中藥研究所(“中藥研究所”或“乙方”)就“防治冠狀病毒性呼吸道感染藥物篩選及藥效評價”合作研究的事宜簽訂《“防治冠狀病毒性呼吸道感染藥物篩選及藥效評價”研究合作協議》，甲方自願委託乙方對相關藥物進行評價研究，負責提供合格樣品並支付相應的實驗研究費用。乙方負責進行相關藥物的有效性評價研究，並形成總結報告。
此次研究內容：開展甲方提供的七種藥物[金感膠囊、雙羊喉痺通顆粒、複方一枝黃花噴霧劑、咳速停糖漿、維C銀翹片、替芬泰(原料/片劑)、糖寧通絡膠囊]在體外和體內五項不同細胞和動物模型，防治冠狀病毒性呼吸道感染藥物篩選及藥效評價試驗。
新型冠狀病毒感染的肺炎正在嚴重威脅全國人民的身體健康，為解決臨牀一線急需，儘快篩選出有效藥物，中國中醫科學院中藥研究所積極參與國家重點研發計劃有關公共安全風險防控和中醫藥防治2019-nCoV病毒研究的工作，擬從國家已上市、有大量臨牀應用基礎的中成藥，以及國家衞健委、中醫藥管理局推薦的肺炎診療方案中緊急篩選出一批療效確切的中成藥品種及有效方劑，為優化臨牀方案和選擇用藥提供科學依據。
承擔此項研究任務的中藥研究所ABSL-2實驗室是專門從事中藥抗感染研究的實驗室，具有10餘種抗感染藥效評價技術及平台。長期承擔上級防治流感重點、重大攻關項目的研究，具有豐富的科研經驗。擁有一支專門從事抗感染研究的高水平科研團隊，在SARS、H1N1流感、人類禽流感等國內歷次突發性公共衞生事件中較好地承擔並完成了國家各項緊急任務。
隨着新型冠狀病毒感染的肺炎疫情持續發酵，公司一直密切關注疫情防控進展，堅決擁護和貫徹落實黨中央、國務院疫情防控工作的重大決策，積極響應政府號召和要求，將防控疫情放在首位。
公司作為工信部和貴州省抗擊疫情重點生產企業，2020年1月29日已提前復工復產，通過充分發揮公司生產規模大、生產能力強的優勢，全力保障公司感冒類、咳嗽類、小兒退熱類、消化道類等藥品的滿負荷生產，確保滿足市場穩定供應，積極支援肺炎疫情防控戰。同時公司結合自身產能大、品種豐富等特點積極履行社會責任，研究制定了多項解決方案和行動措施，決心與國家和全國人民一起努力，為打贏這場疫情防控的阻擊戰發揮應有的作用，貢獻自己的力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
